智慧互聯藥物輸送設備市場機會、成長要素、產業趨勢分析及2026-2035年預測

全球智慧互聯藥物輸送設備市場預計到 2025 年將達到 6.039 億美元，並以 24.6% 的複合年成長率成長，到 2035 年將達到 51 億美元。

市場成長的促進因素包括慢性病負擔的加重、人們對藥物依從性意識的提高以及醫療資訊科技基礎設施的不斷進步。全球智慧互聯藥物輸送設備市場受益於對智慧藥物輸送解決方案日益成長的需求，這些解決方案將藥物傳輸與數位連接相結合，以改善治療管理。這些設備使醫護人員和患者能夠透過互聯的數位平台監測治療狀態、收集治療相關資訊並提高藥物依從率。與行動醫療應用程式、雲端系統和遠端患者監護技術的整合進一步提高了治療效率，並支援個人化醫療方法。此外，人工智慧 (AI) 和機器學習技術的日益普及正在加速整個市場的創新，透過對患者健康資訊和用藥模式的高階分析，實現更精準的治療管理。數位醫療的轉型、互聯醫療生態系統的擴展以及對個人化醫療日益成長的重視，共同為智慧互聯藥物輸送設備市場創造了強勁的長期成長機會。

預計到2025年，整合設備市佔率將達到60.8%。市場對整合系統的需求持續成長，因為這些解決方案將藥物傳輸和數位連接整合到單一設備中，從而提供更高效便捷的用戶體驗。對自動用藥事件記錄、治療資訊無縫傳輸和個人化治療管理的增強支援進一步推動了其普及。人們對連線健診模式和自我給藥療法的日益關注，也進一步促進了對整合智慧互聯藥物傳輸技術的投資。

預計到2025年，居家醫療市場規模將達到2.445億美元。人們對居家護理和自我用藥的偏好日益成長，並持續推動智慧互聯藥物傳輸設備在該領域的強勁需求。患者擴大採用那些能夠在傳統醫療機構之外提供更便捷、柔軟性和持續治療支援的技術。遠端患者監護服務的擴展和數位化醫療解決方案的日益普及正在加速市場成長。互聯藥物輸送設備還有助於與醫療專業人員安全地共用治療訊息，從而幫助提高用藥依從性、加強疾病管理並取得更好的長期臨床療效。

到2025年，北美智慧互聯藥物輸送設備市場佔有率將達到43.4%。慢性病盛行率的不斷上升以及對先進藥物管理解決方案日益成長的需求，正推動著該市場的持續擴張。慢性病相關的長期治療需求，持續推動互聯藥物傳遞技術的應用，這些技術透過即時數據收集和與數位健康技術的整合，支持提高用藥依從性、持續治療監測以及個人化患者照護。

目錄

第1章：調查方法

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 促進因素
    • 提高病人對遵醫囑治療的依從性意識
    • 快速發展的醫療IT基礎設施
    • 機器學習和人工智慧的應用正在迅速成長。
    • 擴大與AR/VR技術整合的遠端醫療平台的應用
  • 產業潛在風險與挑戰
    • 關於病患資料的安全問題
    • 該設備價格昂貴
  • 市場機遇
    • 居家醫療和自我管理的擴展
    • 遠端患者監護的擴展
• 成長潛力分析
• 監理情勢
• 技術展望
  • 最新科技趨勢
  • 新興技術
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 專利分析
• 價格趨勢分析
• 波特的分析
• PESTLE分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 世界
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估價與預測：依產品分類，2022-2035年

• 聯網感測器
  • 連接式進氣感知器
  • 連接式注射感測器
• 整合設備
  • 整合式吸入裝置
  • 一體式注射裝置

第6章 市場估計與預測：依技術分類，2022-2035年

• Bluetooth
• 近距離場通訊
• Wi-Fi

第7章 市場估計與預測：依應用領域分類，2022-2035年

• 過敏反應
• 呼吸系統
• 心血管系統
• 糖尿病
• 荷爾蒙補充療法
• 腫瘤學
• 其他

第8章 市場估算與預測：依最終用途分類，2022-2035年

• 醫院
• 診所
• 居家醫療
• 其他

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • UAE

第10章：公司簡介

• Adherium
• Aptar Pharma
• Becton, Dickinson and Company
• Bayer
• Biocorp
• Eli Lilly and Company
• Enable Injections
• Gerresheimer
• Insulet Corporation
• Medtronic
• Nemera
• Novo Nordisk
• Philips Medisize
• SHL Medical
• Tandem Diabetes Care
• West Pharmaceutical Services
• Ypsomed

The Global Smart Connected Drug Delivery Devices Market was valued at USD 603.9 million in 2025 and is estimated to grow at a CAGR of 24.6% to reach USD 5.1 billion by 2035.

Market growth is supported by the rising burden of chronic diseases, increasing awareness regarding medication adherence, and continuous advancements in healthcare information technology infrastructure. The global smart connected drug delivery devices market is benefiting from growing demand for intelligent drug administration solutions that combine medication delivery with digital connectivity to improve treatment management. These devices enable healthcare providers and patients to monitor therapy, collect treatment-related information, and enhance medication compliance through connected digital platforms. Integration with mobile health applications, cloud-based systems, and remote patient monitoring technologies is further improving treatment efficiency while supporting personalized healthcare approaches. In addition, the increasing use of artificial intelligence and machine learning technologies is accelerating innovation across the market by enabling more accurate therapy management through advanced analysis of patient health information and medication usage patterns. The combination of digital healthcare transformation, expanding connected care ecosystems, and greater emphasis on personalized treatment continues to create strong long-term growth opportunities for the smart connected drug delivery devices market.

The integrated devices segment accounted for 60.8% share in 2025. Market demand for integrated systems continues to increase because these solutions combine drug administration and digital connectivity within a single device, providing a more efficient and convenient user experience. Automated recording of medication events, seamless transmission of treatment information, and enhanced support for personalized therapy management continue to strengthen adoption. Growing interest in connected healthcare models and self-administered therapies is further driving investment in integrated smart connected drug delivery technologies.

The home care settings segment generated USD 244.5 million in 2025. Increasing preference for home-based treatment and self-administration continues to support strong demand for smart connected drug delivery devices in this setting. Patients are increasingly adopting technologies that offer greater convenience, flexibility, and continuous treatment support outside traditional healthcare facilities. Expansion of remote patient monitoring services and broader adoption of digital healthcare solutions continue to accelerate market growth. Connected drug delivery devices also facilitate secure sharing of treatment information with healthcare professionals, helping improve medication adherence, strengthen disease management, and support better long-term clinical outcomes.

North America Smart Connected Drug Delivery Devices Market accounted for 43.4% share in 2025. Continued market expansion is supported by the increasing prevalence of chronic diseases and growing demand for advanced medication management solutions. Long-term treatment requirements associated with chronic conditions continue to encourage adoption of connected drug delivery technologies that improve medication adherence, enable continuous treatment monitoring, and support personalized patient care through real-time data collection and digital health integration.

Major companies operating in the global smart connected drug delivery devices market include Adherium, Aptar Pharma, Becton, Dickinson and Company, Bayer, Biocorp, Eli Lilly and Company, Enable Injections, Gerresheimer, Insulet Corporation, Medtronic, Nemera, Novo Nordisk, Philips Medisize, SHL Medical, Tandem Diabetes Care, West Pharmaceutical Services, and Ypsomed. Companies participating in the smart connected drug delivery devices market are strengthening their competitive position by investing in advanced connected technologies that improve medication management and patient engagement. Manufacturers continue to focus on integrating digital connectivity, artificial intelligence, and data analytics into drug delivery systems to enhance treatment accuracy and personalized care. Product innovation remains a key strategy, with companies developing user-friendly devices that simplify self-administration while improving treatment adherence. Strategic collaborations, expansion of digital healthcare capabilities, and stronger partnerships across healthcare ecosystems are helping companies broaden their market presence.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy and data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail and confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Device type trends
  • 2.2.2 Technology trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
  • 2.2.5 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising patient awareness about adherence to prescribed therapies
    • 3.2.1.2 Rapidly moving healthcare IT infrastructure
    • 3.2.1.3 Soaring adoption of machine learning and artificial intelligence
    • 3.2.1.4 Rising implementation of telehealth platforms integrated with AR/VR technologies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Security concerns regarding patient data
    • 3.2.2.2 High price of devices
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of home-based healthcare and self-administration
    • 3.2.3.2 Growing adoption of remote patient monitoring
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape (Driven by primary research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by primary research)
• 3.7 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.8 Patent analysis
• 3.9 Pricing trend analysis (Driven by primary research)
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
  • 4.2.4 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Connected sensors
  • 5.2.1 Connected inhalation sensors
  • 5.2.2 Connected injectable sensors
• 5.3 Integrated devices
  • 5.3.1 Integrated inhalation devices
  • 5.3.2 Integrated injectable devices

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Bluetooth
• 6.3 Near field communication
• 6.4 Wi-Fi

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Anaphylaxis
• 7.3 Respiratory
• 7.4 Cardiovascular
• 7.5 Diabetes
• 7.6 Hormone replacement
• 7.7 Oncology
• 7.8 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Home care settings
• 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Adherium
• 10.2 Aptar Pharma
• 10.3 Becton, Dickinson and Company
• 10.4 Bayer
• 10.5 Biocorp
• 10.6 Eli Lilly and Company
• 10.7 Enable Injections
• 10.8 Gerresheimer
• 10.9 Insulet Corporation
• 10.10 Medtronic
• 10.11 Nemera
• 10.12 Novo Nordisk
• 10.13 Philips Medisize
• 10.14 SHL Medical
• 10.15 Tandem Diabetes Care
• 10.16 West Pharmaceutical Services
• 10.17 Ypsomed